TAYSHA GENE THERAPIES INC. - COMMON STOCK

Taysha Gene Therapies to Release Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 14

07 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Presents New Preclinical In-vitro Data on TSHA-102 in Rett Syndrome Supporting miRARE Regulation of MECP2 Expression at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

24 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Two Poster Presentations on TSHA-102 in Rett Syndrome at Upcoming European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

10 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome

26 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)

19 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome  

24 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results

14 Aug 2023 07:02:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces $150 Million Private Placement Financing

14 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Positive Recommendation from Independent Data Monitoring Committee of REVEAL Phase 1/2 Trial in Rett Syndrome

31 Jul 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Clinical Updates for Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome at R&D Day

28 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Host Virtual R&D Day on Lead Clinical Investigational Programs TSHA-120 in Giant Axonal Neuropathy (GAN) and TSHA-102 in Rett Syndrome

15 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial Under Investigation for the Treatment of Rett Syndrome

05 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26th Annual Meeting

19 May 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 16:01:01 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

04 May 2023 08:00:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting

27 Apr 2023 16:52:53 By Nasdaq GlobeNewswire

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

28 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28

15 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook

31 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Taysha Gene Therapies Announces Executive Leadership Changes

16 Dec 2022 18:18:58 By Nasdaq GlobeNewswire